Form 4: Sonoma Pharma CEO Granted 10,000 Restricted Stock Units

Sonoma Pharmaceuticals, Inc. CEO Amy Moss Trombly received a grant of 10,000 restricted stock units, vesting over three years.

Summary

• Amy Moss Trombly, Chief Executive Officer of Sonoma Pharmaceuticals, Inc. (SNOA), was granted 10,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was January 2, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs were awarded for services performed and have a conversion or exercise price of $0.00.
• The RSUs will vest on the third anniversary of the grant date, which is January 2, 2029, or upon a change of control.
• Following this transaction, Ms. Trombly beneficially owns 42,185 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it represents a standard compensation practice, it aligns the CEO's interests with the company's long-term performance, which is generally viewed favorably. The minor dilution is a common trade-off for executive retention and motivation.

Positives

• The RSU grant serves as a retention incentive for the Chief Executive Officer, aligning her long-term interests with shareholder value creation.
• Equity-based compensation is a common practice to motivate executives to achieve company performance goals.

Negatives

• The future conversion of RSUs into common stock will result in a minor dilution of existing shareholder equity.

Future Outlook

The granted Restricted Stock Units are set to vest on January 2, 2029, or upon a change of control, indicating a future increase in the CEO's direct ownership of common stock contingent on continued service or a corporate event.

Management Comments

• The Restricted Stock Units were awarded and granted to Ms. Trombly for services performed.

Industry Context

The grant of Restricted Stock Units to a Chief Executive Officer is a standard practice in the pharmaceutical and broader corporate sectors for executive compensation, aiming to align management incentives with long-term company performance and shareholder interests. This type of equity award is a common component of a comprehensive executive compensation package.

Comparison to Industry Standards

• Granting Restricted Stock Units (RSUs) to executive leadership, particularly the CEO, is a widely adopted compensation strategy across industries, including pharmaceuticals. Companies like Pfizer, Johnson & Johnson, and Merck frequently utilize RSUs as a key component of their executive incentive programs to foster long-term commitment and performance.
• The vesting schedule, typically over several years or tied to specific performance milestones or change of control events, is consistent with industry benchmarks designed to retain talent and incentivize sustained growth.
• The 'price' of $0.00 for RSUs is standard, as they represent a right to receive shares rather than an option to purchase them at a set price, differentiating them from stock options.

Related Party Transactions

• The grant of 10,000 Restricted Stock Units to Amy Moss Trombly, the Chief Executive Officer, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also benefits from increased alignment of CEO's interests with long-term company performance.
• Employees: May view this as a standard executive compensation practice, potentially influencing morale if not perceived as equitable across the organization.
• Management: The CEO receives a significant equity award, enhancing her long-term compensation and providing a strong incentive for retention and performance.

Next Steps

• The granted Restricted Stock Units will vest on January 2, 2029, or upon a change of control, at which point they will convert into common stock.

Key Dates

Keywords

Sonoma Pharmaceuticals, SNOA, Restricted Stock Units, RSU grant, executive compensation, beneficial ownership, Form 4, Amy Moss Trombly, CEO